As Jounce’s Vopratelimab Fails, Door Opens For LILRB2 Inhibitor JTX-8064

 
• By Alaric DeArment
Announcing SELECT's failure gives Jounce the chance to shift gears to JTX-8064 • Source: Shutterstock

More from Clinical Trials

More from R&D